MicroRNA 3151 (MIR3151)

MicroRNA 3151 (MIR3151/miR-3151/hsa-mir-3151) is a non-coding RNA molecule involved in the post-transcriptional regulation of gene expression by binding to the 3′-untranslated regions (UTRs) of target mRNAs, leading to their silencing. miR-3151 acts as an oncogenic microRNA (oncomiR) in several cancers. It is known to directly target and downregulate the tumor suppressor TP53, thereby promoting cell proliferation, survival, and resistance to apoptosis in malignant cells, especially in the context of BRAF mutations in melanoma and PTC. In AML, elevated expression of miR-3151 correlates with poor outcomes and drives cancer pathology through the repression of key regulators such as MEIS1, PDCD4, FBXL20, and USP40. Experimental strategies targeting miR-3151 (e.g., through antagomiRs) restore TP53 function and sensitize tumor cells to apoptosis. Combination approaches with BRAF inhibitors like vemurafenib demonstrate enhanced therapeutic efficacy in resistant melanoma cell models, suggesting miR-3151 is a promising therapeutic target and biomarker in oncology.

Other names

miR-3151hsa-mir-3151MIR3151

Drugs targeting miR-3151 (e.g., antagomiRs) act by inhibiting its function; this de-represses direct targets such as TP53, increasing apoptosis and reducing tumor cell proliferation. Combination therapies (e.g., BRAF inhibitors and miR-3151 inhibition) enhance anti-tumor activity via multi-pathway suppression.